https://www.selleckchem.com/products/cd532.html
ies, with no impact of age. The present study shows that among ACS patients randomized in the REDUCE trial, a 3-month DAPT strategy was comparable to a standard 12-month DAPT at a 2-year follow-up for both ischemic and bleeding endpoints, in elderly and younger patients. Thus, despite presenting the limitations of a subgroup analysis, our study strengthens the feasibility of a shorter DAPT duration even among high-risk subsets of ACS patients. The present study shows that among ACS patients randomized in the REDUCE trial, a 3-month DAPT s
Like
Comment
Share
